Beta-Blocker Selection in Heart Failure and Hypertension

Heart Failure Management

The European Society of Cardiology recommends bisoprolol for heart failure treatment, with a proven 34% reduction in all-cause mortality in large randomized trials, and a Class I, Level A evidence rating 1, 2, 3, 4
Bisoprolol reduces hospitalizations, improves functional class, and prevents worsening of heart failure across all subgroups, regardless of age, gender, LVEF, or etiology 1, 2
The CIBIS-II trial demonstrated that bisoprolol reduced sudden deaths by 44% and pump failure deaths by 26% in NYHA class III-IV heart failure patients 5

The American Heart Association and European Society of Cardiology suggest that bisoprolol's beta-1 selectivity is crucial for heart failure efficacy, as it blocks chronic beta-1 stimulation-induced myocardial apoptosis, necrosis, and inflammation while minimizing beta-2 blockade side effects 1, 2, 3, 4
Bisoprolol has a 10-12 hour half-life with balanced renal and hepatic elimination, allowing reliable once-daily dosing, with a target dose for heart failure of 10 mg once daily 6
Propranolol is not recommended for heart failure treatment due to its non-selective beta-blockade and lack of proven mortality benefit in this population 1, 2, 3, 4

The European Society of Cardiology recommends choosing bisoprolol when heart failure with reduced ejection fraction is present, post-myocardial infarction with LV dysfunction, hypertension with LV hypertrophy, or in patients with mild-moderate COPD or reactive airway disease 1, 2, 6
Propranolol has limited modern indications, including specific arrhythmias, migraine prophylaxis, essential tremor, and anxiety disorders, but is not recommended for heart failure treatment 1, 3